Presentation is loading. Please wait.

Presentation is loading. Please wait.

Regulatory Perspective

Published byBetty Blake Modified over 6 years ago

Similar presentations

Presentation on theme: "Regulatory Perspective"— Presentation transcript:

1 Regulatory Perspective
John Koerner, Ph.D. Senior Pharmacologist CDER, DCRP

2 Disclaimer The views expressed are those of the presenter and do not necessarily reflect those of the FDA 2

3 Objectives of SP Studies
This (S7A) guideline was developed to help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals, while avoiding unnecessary use of animals and other resources. 3

4 ICH Guidances ICH S7A – Safety Pharmacology
“Some safety pharmacology endpoints can be incorporated in the design of toxicology (studies) … “ ICH S6 – Biotechnology Products ICH S9 – Oncology Products 4

5 For First in Human Studies
Capture relevant CV safety signals to prevent catastrophic, life-threatening AEs HR, BP and ECG 5

6 Reduce attrition throughout development
Worthwhile goal A regulatory issue when a safety concern to clinical trial participants – say, negative contractility in a fragile patient population. 6

7 Stand-Alone CV Safety Pharm Study
Conscious, telemeterized animals Typically cross-over design Experience with standard drugs Known (and predictable) sensitivity 7

8 CV Endpoints in Toxicology Studies
Sensitivity compared to stand-alone study? i.e., what can the study capture, and is this good enough? How best to demonstrate this sensitivity? 8

9 Safety Pharmacology Recommendations
SPS – Best Practices* HESI Cardiovascular Safety Committee ^ * Best Practice in the conduct of key nonclinical CV assessments…; Leishman, et.al. ^ Cardiovascular Function in nonclinical drug safety assessment…; Sarazan, et.al. 9

10 Thank you

Download ppt "Regulatory Perspective"

Similar presentations

FDA\ CDER\OPASS\OB ASA-Industry Workshop,Sept.17- 19,2000 Bethesda, MD Multi-Clinic and Multi-National Trials: A regulatory perspective Charles Anello.

FDA\ CDER\OPASS\OB ASA-Industry Workshop,Sept ,2000 Bethesda, MD Multi-Clinic and Multi-National Trials: A regulatory perspective Charles Anello.
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)

Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)
Integrating Cardiovascular Endpoints into toxicology studies: Preliminary Results from An Industry Survey Simon Authier, DVM, MBA, PhD Director - Safety.

Integrating Cardiovascular Endpoints into toxicology studies: Preliminary Results from An Industry Survey Simon Authier, DVM, MBA, PhD Director - Safety.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.

1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.
Mitochondrial Manipulation Technologies: Preclinical Considerations

Mitochondrial Manipulation Technologies: Preclinical Considerations
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.

Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
2014-01-22Stefan Franzén Introduction to clinical trials.

Stefan Franzén Introduction to clinical trials.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.

Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / 15-19 October 2007 1 |1 | Regulatory Requirement on Dossier of Medicinal.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.

CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.

Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Justina A. Molzon, MS Pharm, JD

Justina A. Molzon, MS Pharm, JD

Similar presentations

Ads by Google